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Abstract 45 
Cell therapies to treat critical limb ischaemia have demonstrated only modest results in 46 
clinical trials, and this has been partly attributed to poor cell retention following their delivery 47 
directly into the ischaemic limb. The aim of this study was to determine whether alginate-48 
encapsulation of therapeutic pro-angio/arteriogenic macrophages enhances their retention 49 
and ultimately improves limb perfusion. A reproducible GMP-compliant method for 50 
generating 300µm alginate capsules was developed to encapsulate pro-angio/arteriogenic 51 
macrophages. Longitudinal analysis revealed no detrimental effect of encapsulation on cell 52 
number or viability in vitro, and macrophages retained their pro-angio/arteriogenic 53 
phenotype. Intramuscular delivery of encapsulated macrophages into the murine ischaemic 54 
hindlimb demonstrated increased cell retention compared with injection of naked cells 55 
(P=0.0001), and that this was associated both enhanced angiogenesis (P=0.02) and 56 
arteriogenesis (P=0.03), and an overall improvement in limb perfusion (P=0.0001). Alginate 57 
encapsulation of pro-angio/arteriogenic macrophages enhances cell retention and 58 
subsequent limb reperfusion in vivo. Encapsulation may therefore represent a means of 59 
improving the efficacy of cell-based therapies currently under investigation for the treatment 60 
of limb ischaemia. 61 
 62 
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Abbreviations: 70 
α-SMA  α-smooth muscle actin 71 
Ang-1/-2 angiopoietin-1/-2 72 
CLI  critical limb ischaemia 73 
EC  endothelial cell 74 
HUVEC human umbilical vein endothelial cell 75 
iBMMs immortalised bone marrow macrophages 76 
IL-10  interleukin-10 77 
IL-1  interleukin-1beta 78 
eiBMMs encapsulated immortalised bone marrow macrophages 79 
niBMMs naked immortalised bone marrow macrophages 80 
MCP-1  monocyte chemoattractant protein-1 81 
MMP9  matrix metalloproteinase 9 82 
MRC1  mannose receptor C-type 1 83 
M-CSF  macrophage colony stimulating factor 84 
PAD  peripheral arterial disease 85 
PI  propidium iodide 86 
PlGF-2 placenta growth factor-2 87 
VEGF  vascular endothelial growth factor 88 
 89 
 90 
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Introduction 91 
Critical limb ischaemia (CLI) is a severe manifestation of peripheral arterial disease (PAD) 92 
that is characterised by pain and gangrene.1 The limb salvage rate for patients with CLI 93 
remains poor,2 with a significant proportion of patients not amenable to standard treatments, 94 
including surgical bypass and angioplasty. This has been the driver for the development of 95 
angiogenic cell-based therapies aimed at limb salvage in these no option patients. Clinical 96 
trials of cell therapy to date have only shown a modest benefit with disappointing results 97 
attributed to the lack of potency of cells injected, including a functional impairment of 98 
autologous cells harvested from patients with multiple co-morbidities. 3-10  99 
The poor retention of cells after injection into the target site is also thought to limit their 100 
potential for effecting robust collateralisation. Cells injected directly into the calf muscle are 101 
susceptible to clearance by immune cells or apoptosis triggered by the hypoxic, pro-102 
inflammatory environment.11 Mononuclear cells injected intramuscularly in the ischaemic 103 
hindlimb have a short-lived survival, which is not improved with repeated injection.12 There 104 
are currently no studies to assess retention of cells injected into the ischaemic limb in man, 105 
but clinical studies of therapeutic cell injection into the heart reveal a similar precipitous loss, 106 
with only ~12% of cells retained after 1 hour.13 107 
The use of implantable biomaterials, containing therapeutic cells, to enhance cell-based 108 
therapies is gaining traction in a number of cell therapy areas, including the use of bone-109 
marrow derived mesenchymal stem cells for revascularisation of infarcted myocardium and 110 
ischaemic hindlimbs.14,15 Encapsulation in polymeric matrices, including alginate, can be 111 
used to deliver therapeutic cells as it not only enhances cellular retention and survival,16,17 112 
but also provides a semi-permeable membrane for diffusion of nutrients, stimulants and 113 
waste products.18   114 
Alginate is an unbranched algae-derived polysaccharide, which gels upon contact with 115 
divalent cations.19 Its biocompatibility, paired with ease of use makes it an attractive option 116 
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for the development of cell therapy. We have previously identified a subset of human 117 
monocyte/macrophages that promote limb revascularisation in mice20 and carried out a first 118 
in man study involving delivery of this subset in patients with limb ischaemia (unpublished 119 
data). Here, we use murine pro-angio/arteriogenic macrophages to optimise and standardise 120 
a GMP-compliant encapsulation strategy, and to study the effect of this procedure on their 121 
viability and capacity to enhance revascularisation of the ischaemic limb, in readiness for 122 
clinical trials in patients with limb ischaemia. 123 
 124 
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 131 
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 133 
 134 
 135 
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Results 137 
Optimisation of alginate capsule generation 138 
A number of encapsulation parameters were optimised to allow reproducible generation of 139 
capsules of a consistent shape and diameter, prior to generating cell-seeded capsules for 140 
subsequent in vitro and in vivo experiments. Capsule diameter was affected by increasing 141 
the flow rate of alginate solution through the cell encapsulator, but varying the concentration 142 
of sodium alginate had little effect (Fig. 1a). Increasing the voltage applied to the alginate 143 
suspension decreased the capsule diameter (Fig. 1b). A flow rate of 12ml/min, with 1.0% 144 
sodium alginate and 6.8kV reliably produced capsules of 300µm diameter and a round 145 
shape (Fig. 1a, c).  146 
In order to standardise experimental conditions, we encapsulated immortalised murine bone 147 
marrow-derived macrophages engineered to express the Tie2 receptor (Tie2-iBMMs, see 148 
Methods) to provide a uniform population of angiogenic cells for these  proof-of-concept 149 
studies aimed at developing a standardised GMP-compliant encapsulation method and 150 
deciphering the effect of encapsulation on cells. Uniformly seeded capsules were produced 151 
when Tie2-iBMMs were seeded into the alginate solution at a concentration of 1x107 152 
cells/ml, with capsules containing approximately 200 cells each (Fig. 1c). 153 
 154 
The effect of encapsulation on Tie2-iBMM viability and phenotype 155 
(i) Encapsulated Tie2-iBMM viability and number is maintained during culture in vitro 156 
Encapsulated Tie2-iBMMs (eTie2-iBMMs) were assessed longitudinally, in vitro, for cell 157 
viability and phenotype in order to ascertain whether encapsulation was detrimental to cell 158 
health (Fig, 2, Table 1). Microscopic analysis of the capsules demonstrated maintenance of 159 
capsule integrity and retention of the cells within the capsules up to day 21 post-160 
encapsulation (Fig. 2a-d). There was no significant loss of cells from the capsules in vitro up 161 
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to day 21 (Fig. 2e, day 0: 196±2.5 vs day 21: 188±1.4 cells/capsule). Analysis of cell viability 162 
by annexin V and PI staining (Fig. 2f, g, Table 1), across 7 days in vitro, demonstrated that 163 
the majority of cells remain viable. 164 
 165 
(ii) Tie2-iBMM phenotype is not affected by alginate encapsulation and long-term in 166 
vitro culture 167 
We assessed the phenotype of macrophages following long-term in vitro culture of Tie2-168 
iBMMs in alginate capsules. After 21 days, the expression of Tie2 and the mouse 169 
macrophage marker, F4/80, on naked Tie2-iBMMs (nTie2-iBMMs) remained constant and 170 
was comparable to that of eTie2-iBMMs (Fig. 2h, Supplementary Data, Table S1). 171 
Expression of the ‘M1’ macrophage markers CD80 and CD86 did not differ between nTie2-172 
iBMMs and eTie2-iBMMs at any time point (Fig. 2h, Supplementary Data, Table S1). 173 
Expression of MRC1, an ‘M2’ macrophage marker, was not significantly different between 174 
nTie2-iBMMs and eTie2-iBMMs at any time point (Fig. 2h, Supplementary Data, Table S1). 175 
 176 
The effect of alginate encapsulation on Tie2-iBMM function 177 
(i) Encapsulated Tie2-iBMMs promote angiogenesis in vitro 178 
Quantification of HUVEC tubule formation induced by culturing in the presence of either 179 
empty capsules (Fig. 3a), vascular endothelial growth factor (Vegfa, Fig. 3b), nTie2-iBMMs 180 
(Fig. 3c) or eTie2-iBMMs (Fig. 3d) demonstrated increased endothelial cell (EC) tubule area 181 
in eTie2-iBMM co-cultures compared with empty capsules (Fig. 3e, P=0.002), and this was 182 
comparable to that induced by the Vegfa positive control (P>0.1) and nTie2-iBMMs (P>0.9). 183 
In order to determine whether encapsulation of Tie2-iBMMs affected the secretion of factors 184 
that may promote or inhibit angiogenesis, we compared the conditioned media produced by 185 
nTie2-iBMMs and eTie2-iBMMs left in culture up to 21 days. We found a significantly higher 186 
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expression of PlGF-2 and Vegfa 7, 14 and 21 days following encapsulation of Tie2-iBMMs 187 
compared with non-encapsulated cells (Fig. 3f, Supplementary Data, Table S2). Expression 188 
of MMP9 was significantly higher in eTie2-iBMMs compared with nTie2-iBMMs at days 3, 7 189 
and 14 post-encapsulation (Fig. 3f, Supplementary Data, Table S2). Secretion of the pro-190 
inflammatory cytokine IL-1 was not affected by encapsulation, however, expression of the 191 
anti-inflammatory cytokine IL-10 was significantly greater at day 7 following encapsulation 192 
(Fig. 3f, Supplementary Data, Table S2). 193 
We sought to establish whether cell encapsulation hindered the signalling of pro-angio-194 
/arteriogenic cells via soluble ligand binding (angiopoietins), as the cytokine milieu in the 195 
ischaemic limb is thought to modulate injected therapeutic cells in this manner.20 Moreover, 196 
for encapsulated cells to exert their beneficial effect, the biomaterial used must not 197 
deleteriously affect the secretion of soluble factors that may promote tissue regeneration in a 198 
paracrine fashion. TIE2 receptor phosphorylation can be induced by both Ang-1 and Ang-2, 199 
although there is debate as to which ligand induces the most potent angiogenic response in 200 
TEMs.20 The secretion of Vegfa by Tie2-iBMMs stimulated with Ang-1 and Ang-2 was not 201 
different between naked and encapsulated cells (Fig. 3g). As well as assessing the effect of 202 
encapsulation on the paracrine function of Tie2-iBMMs, we sought to investigate whether 203 
production of chemokines involved in monocyte recruitment to the ischaemic limb was 204 
affected. Monocyte chemoattractant protein-1 (MCP-1) promotes the recruitment of 205 
monocytes to the ischaemic limb, which subsequently differentiate into M2 macrophages 206 
and enhance arteriogenesis.21-23 MCP-1 production was greater in eTie2-iBMMs compared 207 
with nTie2-iBMMs following stimulation by both Ang-1 and Ang-2 (Fig. 3h, P<0.01 for both), 208 
indicating that eTie2-iBMMs may act not only through enhanced paracrine function, but also 209 
through recruitment of cells implicated in driving a pro-arteriogenic response.  210 
(ii) Encapsulation of therapeutic macrophages improves their retention in the murine 211 
ischaemic hindlimb 212 
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Given that in vitro culture demonstrated Tie2-iBMM viability and phenotype could be 213 
maintained after prolonged encapsulation within alginate capsules, we assessed whether 214 
eTie2-iBMMs were better retained following delivery into the murine ischaemic hindlimb 215 
compared with naked cells. We found that although there was a reduction in biofluorescence 216 
in both treatment groups over 28 days (Fig. 4a), eTie2-iBMMs were significantly better 217 
retained at days 7, 14 and 21 than nTie2-iBMMs (Fig. 4b, P<0.0001).  218 
(iii) Revascularisation of the ischaemic murine hindlimb is enhanced by alginate 219 
encapsulation of Tie2-iBMMs 220 
Encapsulated Tie2-iBMMs induced greater reperfusion of ischaemic hind limbs than 221 
treatment with nTie2-iBMMs (P<0.01). Mice injected with eTie2-iBMMs or nTie2-iBMMs 222 
demonstrated greater revascularisation of the ischaemic limb over 21 days compared with 223 
animals treated with empty alginate capsules (Fig. 5a, b,  P<0.0001 and P<0.05 224 
respectively). Histological analysis revealed an increase in the number of arterioles, (Fig. 5c, 225 
f, P=0.03), and a trend to increased arteriole diameter (Fig. 5d, f, P=0.057) of α-SMA+ 226 
arterioles; as well as increased angiogenesis (capillary:fibre ratio, Fig. 5e, f, P=0.023) in 227 
ischaemic muscle specimens of mice treated with eTie2-iBMMs compared with nTie2-228 
iBMMs. Mice treated with empty alginate capsules had significantly less angiogenesis and 229 
arteriogenesis compared with those treated with eTie2-iBMMs (Fig. 5c-e, P=0.01). Alginate 230 
capsules persisted in the hindlimb after 21 days (Fig. 5g), and still contained cells at this time 231 
(Fig. 5h). 232 
(iv) Delivery of alginate-encapsulated macrophages does not induce tissue 233 
inflammation, apoptosis or muscle damage in the ischaemic limb 234 
There was no significant difference in the number of CD45+ cells in hindlimbs injected with 235 
eTie2-iBMMs compared with nTie2-iBMMs (Fig. 6a). Deep phenotyping of the CD45+ 236 
population showed no significant difference in the proportion of neutrophils (CD11b+Ly6G+), 237 
or monocytes and macrophages (CD11b+Ly6G- and CD11b+F4/80+ cells, Fig. 6b-d, 238 
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Supplementary Data, Table S3). Treatment with eTie2-iBMMs was associated with a 239 
significantly reduced proportion of the endogenous CD11b+Ly6G- monocytes expressing 240 
Ly6C (Ly6Chigh, Fig. 6e, Supplementary Data, Table S3) compared with nTie2-iBMM and 241 
empty capsule-treated mice (P<0.05). Histological analysis of muscle specimens revealed 242 
no significant difference in the number of cells expressing the apoptosis marker activated 243 
caspase-3 between treatment groups (Fig. 6f, g), or any difference in muscle damage 244 
between treatment groups (Fig. 6f, h). 245 
 246 
 247 
 248 
249 
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Discussion  250 
To date, cell-based therapies for the treatment of CLI have demonstrated limited efficacy in 251 
clinical trials.4-6 A possible contributing factor to these modest results is poor cell retention 252 
following direct injection of cells into the ischaemic limb. This suggests a need for an 253 
alternative delivery system, such as encapsulation of therapeutic cells within a biocompatible 254 
material prior to implantation that promotes cell retention to ensure a better outcome.  255 
This study investigates the effect of alginate encapsulation on the phenotype and function of 256 
a pro-angio/arteriogenic murine macrophage line (Tie2-iBMMs), in revascularising the 257 
ischaemic limb. We describe a GMP-compliant methodology for the consistent generation of 258 
uniform alginate capsules containing these cells that does not adversely affect their viability, 259 
phenotype and function in vitro. Encapsulation enhanced Tie2-iBMM retention following 260 
implantation into the ischaemic hindlimb and this was associated with significantly greater 261 
angio/arteriogenesis and overall limb revascularisation compared with non-encapsulated 262 
Tie2-iBMMs. 263 
Tie2-expressing macrophages are thought to facilitate revascularisation either through a 264 
paracrine action24,25 or via direct contact with endothelial cells26 and, therefore, their utility as 265 
therapeutic cells necessitates their delivery in close proximity to an ischaemic region to 266 
maximise their revascularisation potential.27 Maintenance of their retention at the site of 267 
delivery is thought to be another important factor in achieving optimal therapeutic benefit, 268 
with significant cell loss from the site of implantation noted when directly injected into both 269 
the ischaemic heart and limb.12,28 Cell encapsulation maintains retention and has proved 270 
efficacious in different clinical settings including pancreatic islet cell and hepatocyte 271 
transplantation for the treatment of diabetes and liver failure.29,30 The data presented 272 
demonstrates that Tie2-expressing macrophage secretion of pro-angio/arteriogenic 273 
cytokines is preserved or even enhanced following encapsulation. PlGF-2, VEGF and MMP9 274 
have proven potential for promoting ischaemic tissue repair through induction of 275 
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angiogenesis, progenitor cell recruitment and improved integration of injected cellular 276 
biomaterials and, therefore, the greater degree of limb reperfusion in eTie2-iBMM-treated 277 
animals could be attributed to the improved retention of these cells in the ischaemic region, 278 
facilitating the action of these growth factors.31-33 In addition to providing a physical barrier 279 
for preventing cell loss through wash out by the vascular and lymphatic systems, alginate 280 
encapsulation of cells has also been shown to inhibit migration of cells out of the capsule 281 
into the surrounding host tissues.15 282 
An advantage of encapsulating cells, in addition to improving retention, is their 283 
immuneprivileged status within the capsule.34 Although immunogenicity is not a 284 
consideration when using autologous cells for therapeutic purposes, murine studies suggest 285 
that co-morbidities associated with CLI can adversely affect the angio/arteriogenic potential 286 
of monocyte/macrophages.35 Allogeneic macrophages from healthy individuals, that may 287 
have more potent angio/arteriogenic properties for promoting limb salvage, could be used in 288 
combination with encapsulation technologies, to enhance the efficacy of cell-based 289 
strategies. The protection from host immunity conferred by encapsulation of cells from 290 
allogeneic sources, warrants further investigation in the context of ischaemia. CLI patients 291 
frequently suffer with multiple co-morbidities, and the functional potency of their cells should 292 
be compared with those isolated from healthy subjects in order to determine the most 293 
suitable source of cells for successful therapy. 294 
The present study highlights the promise offered, through the use of a GMP-compliant 295 
biomaterial encapsulation process, to enhance the efficacy of cell therapies for treating limb 296 
ischaemia. We employed the murine macrophage iBMM cell line in our experiments to 297 
ensure replicability and fair comparison in our proof of concept study. Further studies, using 298 
human macrophages in place of the mouse cell line tested here, would be required to allow 299 
the translation of this work into clinical trials. Here we show not only an improvement in the 300 
method for delivering cells, but also the potential for a whole new cell product for therapeutic 301 
use when human macrophages are encapsulated under GMP conditions. Sodium alginate is 302 
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a well-established material for the purposes of cell encapsulation, although there now exists 303 
an expansive range of biomaterials that have been engineered to specifically promote the 304 
reparative function of cells contained therein.36-38 Biomaterial-based cell therapies may be 305 
further enhanced through engineering to allow for the temporal release of pro-306 
angio/arteriogenic factors that may increase the potency of encapsulated cells. Growth-307 
factor-containing hydrogel cores within alginate microcapsules are postulated to improve cell 308 
survival,39 with MSC-VEGF co-encapsulation demonstrating promise in the treatment of 309 
myocardial infarction.40 Co-encapsulation of different cells may also enhance therapeutic cell 310 
function and survival.41,42 It is possible therefore, that although the present study highlights 311 
the benefit of cellular encapsulation in promoting retention of therapeutic cells and their 312 
activity in revascularising the ischaemic limb, there could be scope for further improvements 313 
to enhance their efficacy through the development of co-encapsulation modalities. 314 
In summary, these studies provide an optimised methodology for the generation of alginate 315 
capsules containing pro-angio/arteriogenic macrophages, and show that encapsulation in 316 
this biopolymer is not detrimental to cell viability, phenotype or function. These data show 317 
that encapsulation both enhances macrophage retention and their pro-318 
angiogenic/arteriogenic potential in the ischaemic murine hindlimb, which leads to greater 319 
limb perfusion, compared with naked cells. This work may have important implications for 320 
cell-based therapies currently being trialled for treatment of CLI. 321 
 322 
 323 
 324 
 325 
 326 
 327 
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Methods 328 
Cell culture 329 
Murine bone marrow-derived macrophages were immortalised using a lentiviral vector 330 
containing the SV40 large T Antigen coding sequence to form iBMMs.43 Vesicular stomatitis 331 
virus-pseudotyped, third generation lentiviruses were produced by plasmid transfection of 332 
293T cells. The SV40 large T antigen coding sequence was cloned into the SFFV promoter-333 
containing lentivirus using BamHI and SaII restriction enzymes, and the resultant lentivirus 334 
used for transduction. Tie2 expression was subsequently induced via a second lentiviral 335 
transduction.43,44 Tie2-iBMMs were cultured in complete medium (IMDM (Gibco, UK), 20% 336 
foetal calf serum (FCS) containing 2mM glutamine, 1% (v/v) antibiotic/antimycotic and 337 
50ng/ml macrophage colony stimulating factor (M-CSF, Peprotech, UK)) under standard 338 
conditions (37°C, 21% O2, 5% CO2). 339 
Encapsulation of Tie2-iBMMs 340 
SLG20 alginate (1.5% (w/v), Pronova Biomedical) was prepared in 0.9% (w/v) NaCl, and 341 
cells resuspended in alginate at a concentration of 1.0x107 cells/ml. Capsules were 342 
generated using a Good Manufacturing Practice (GMP)-compliant BUCHI B-395 Pro 343 
encapsulator, set at a flow rate of 12.0ml/min, with the cell solution passing through a 120µm 344 
nozzle vibrating at 1800Hz, and a 6.8kV electric field, into a polymerisation solution (1.2% 345 
(w/v) CaCl2, 0.9% (w/v) NaCl, Tween-20). Capsules were subsequently washed in 0.9% 346 
(w/v) NaCl. Capsule diameter and cell number/capsule was determined by counting the 347 
number of cells within 10 capsules from 3 separate experiments under a brightfield 348 
microscope. The GMP-grade encapsulation system generated sterile capsules that 349 
contained the murine macrophage cell line in order to minimise the possibility of infection 350 
and hence any inflammation that might confound our revascularisation results in our animal 351 
HLI model.  352 
 353 
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Digestion of alginate capsules 354 
Capsules were centrifuged to remove media (300g, 5mins) and resuspended in chelation 355 
solution (30mM EDTA in 55mM sodium citrate), prior to 5min incubation at 37°C with regular 356 
vortexing. The digestion solution was passed through a 70µm cell strainer to remove 357 
undigested alginate. Cells from the digested capsules were washed and centrifuged at 300g 358 
for 5min to pellet.  359 
Preparation of single-cell suspensions from ischaemic muscle for flow cytometry 360 
Adductor muscle samples were harvested from treated animals 7 days after the procedure. 361 
Briefly, cells were isolated from dissected tissue following 30 minute incubation in a tissue 362 
digestion buffer (0.5% BSA, 1mg/ml collagenase, 1mM EDTA, 500units/ml hyaluronidase, 363 
100units/ml DNase I in dPBS (Sigma)). Filtered tissue digests were subject to red blood cell 364 
lysis (BD Bioscience) and washed prior to staining and analysis using flow cytometry. 365 
Flow Cytometry 366 
Cell viability and phenotype were assessed using either a MACSQuant (Miltenyi Biotec, UK) 367 
or AttuneNxT (Thermo Scientific, UK) flow cytometer. Cells were harvested from (i) 368 
monolayer culture (naked - nTie2-iBMMs) and alginate capsules (encapsulated - eTie2-369 
iBMMs) at days 1, 3, 5, 7, 14 and 21 post-encapsulation; and (ii) digested adductor muscle 370 
specimens. Cells were washed and FcR receptors blocked using FcR blocking reagent 371 
(Miltenyi Biotec, UK). Cell viability was determined using a Live-Dead Staining Kit (Thermo 372 
Fisher Scientific, UK) for annexin V and PI according to manufacturer’s instructions. 373 
Antibodies for assessment of cell phenotype or muscle cell content are listed in 374 
Supplementary Data, Table S4. All experiments utilised fluorescence minus one (FMO) 375 
controls to determine positive cell surface expression, and analysis of acquired data was 376 
carried out using FlowJo V10 software. Gating panels are detailed in Supplementary Data, 377 
Figures S5 and S6. 378 
In vitro angiogenesis assay 379 
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The angiogenic potential of eTie2-iBMMs was assessed using a previously-described 380 
HUVEC/fibroblast co-culture assay,45 and compared with HUVEC tubule formation induced 381 
by empty alginate capsules. Media containing 100ng/ml VEGF was used as a positive 382 
control. HUVEC tubule formation was quantified after 14 days using ImageProPlus software.  383 
Luminex quantification of secreted cytokines 384 
A custom Luminex assay (R&D Systems, UK) for murine PlGF-2, VEGF, MMP9, IL-1 and 385 
IL-10 was used to quantify secreted protein levels in conditioned media collected from nTie2-386 
iBMM and eTie2-iBMM cell cultures at days 3, 7, 14 and 21. The assay was carried out 387 
according to manufacturer’s instructions, and data captured using a Bio-Plex MAGPIX 388 
system (BioRad, UK). 389 
Vegfa and MCP-1 ELISA 390 
The secretion of Vegfa and MCP-1 by Ang-1/Ang-2-stimulated Tie2-iBMMs was assessed 391 
using ELISA (R&D Systems, UK) according to manufacturer’s instructions. Briefly, either 392 
nTie2-iBMMs or eTie2-iBMMs were stimulated with 200ng/ml Ang-1 or Ang-2 for 24 hours. 393 
Media was then replaced with serum-free iBMM media for a further 24 hours and 394 
conditioned media subsequently collected for analysis.  395 
Animal source and husbandry 396 
Male C57BL/6 mice aged 8-10 weeks were procured from Charles River Laboratories. All 397 
animals were randomised prior to experimentation and during acquisition of data, observers 398 
were blinded to these allocations. Animals were maintained in individually ventilated cages, 399 
and their health status monitored throughout the course of the experiment to ensure 400 
compliance with U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines. 401 
In vivo biofluorescence 402 
Tie2-iBMMs were stained with VivoTrack680 biofluorescent dye (Perkin Elmer, UK) 403 
according to manufacturer’s instructions. Cells were then either directly injected into the 404 
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adductor muscle of mice undergoing hindlimb ischaemia surgery, or encapsulated in alginate 405 
prior to implantation in operated mice. Each mouse received 1x106 Tie2-iBMMs. Radiance 406 
efficiency was quantified using an IVIS Spectrum In Vivo imaging system (Perkin Elmer) at 407 
days 0, 3, 7, 14, 21 and 28 using a 60 second exposure time to assess changes in 408 
fluorescence intensity using Living Imaging v4.5 software. 409 
Murine model of hindlimb ischaemia (HLI) 410 
Unilateral hindlimb ischaemia was surgically induced in 8-week-old C57BL/6 male mice 411 
(n=15/group) by ligation of the femoral artery proximal and distal to the profunda femoris and 412 
excision of the intervening segment. nTie2-iBMMs were either directly injected into the 413 
adductor muscle or encapsulated and layered onto the muscle. Empty alginate capsules 414 
were layered onto the muscle as a control. Paw perfusion was quantified by laser Doppler 415 
perfusion imaging (LDPI, Moor Instruments, UK) at 3, 7, 14 and 21 days. Adductor and 416 
gastrocnemius muscles were harvested at day 21 for histological analysis. 417 
Histological analysis 418 
Muscle specimens were fixed in 4% paraformaldehyde and dehydrated in increasing 419 
concentrations of sucrose (15%, 30%, and 40%) prior to snap-freezing in isopentane. Five 420 
consecutive 10m sections were stained from three areas of each muscle specimen (500m 421 
separation), and analysed for measures of either arterio- or angiogenesis. Arteriogenesis 422 
was measured in adductor muscle specimens by staining for -smooth muscle actin (-423 
SMA) and laminin; whilst angiogenesis, in gastrocnemius muscle, was measured by 424 
quantification of capillary:fibre ratio using antibodies against CD31-PECAM and laminin. The 425 
number of CD45+ cells per field of view was quantified in adductor muscle specimens and 426 
cell apoptosis quantified by staining for activated Caspase-3. Antibody information is listed in 427 
Supplementary Table S4. Cell retention within implanted capsules, harvested from the 428 
operated limb at day 21, was analysed using H&E stain. Muscle fibre damage in the 429 
ischaemic limb was assessed by H&E staining of ischaemic adductor muscle sections, with 430 
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fibres characterised as normal, damaged or regenerating using a standard protocol.46 431 
Fluorescent and histological staining was assessed with a Nikon Ti Eclipse microscope 432 
using NIS-Elements BR microscopy software. 433 
Statistical analysis 434 
All statistical analysis was performed using GraphPad Prism 7 software. Technical and 435 
experimental repeats were conducted to ensure that experiments were powered to at least 436 
80%. Statistical significance was analysed by 1- or 2-way ANOVA and appropriate post-hoc 437 
tests, or by Mann Whitney/Kruskal Wallis test, as specified in the figure legends. A threshold 438 
of P<0.05 was defined as statistically significant. Data is presented as mean±SD. 439 
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Data availability 454 
The data that supports the findings of this study are available from the corresponding author 455 
upon reasonable request. 456 
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Figure Legends 635 
Fig. 1 Optimisation of capsule generation. (a) The diameter of alginate capsules generated 636 
under a range of alginate concentrations (0.8% and 1.0%), and encapsulator flow rates (2-637 
12ml/min) was measured microscopically (n=10/group). (b) Variation of the encapsulator 638 
voltage settings influenced the diameter of capsules generated (n=5/group, error bars=s.d.). 639 
(c) Consistently round 300µm diameter capsules were generated using 1.0% alginate with a 640 
flow rate of 12ml/min and were used to encapsulate Tie2-iBMMs at a cell density of 1x107 641 
cells/ml. Scale bar = 100µm. 642 
Fig. 2 The effect of prolonged encapsulation on Tie2-iBMMs. (a-d) Alginate capsules seeded 643 
with Tie2-iBMMs at days (a) 1, (b) 7, (c) 14 and (d) 21 post-encapsulation. (e) Tie2-iBMM 644 
retention within the capsules was quantified up to day 21 following encapsulation 645 
(n=5/group, P=n/s by 1way ANOVA). (f) Flow cytometric analysis of cell viability using 646 
annexin V/PI staining (Q1 = cell debris; Q2 = dead cells; Q3 = apoptosing cells; Q4 = live 647 
cells). (g) Quantification of annexin V/PI staining of encapsulated Tie2-iBMMs at days 1, 2, 3 648 
and 7 post-encapsulation (n=4/group, P=n/s by 2way ANOVA and Bonferroni post-test). (h) 649 
Measurement of cell phenotype by flow cytometry in nTie2-iBMMs (green) and eTie2-iBMMs 650 
(grey) up to 21 days in vitro (n=5/group, P=n/s P<0.001 by 2way ANOVA and P=n/s 651 
Bonferroni post-test). Error bars=s.d. Scale bar = 100µm. 652 
Fig. 3 The effect of alginate encapsulation on the pro-angiogenic function of Tie2-iBMMs. (a-653 
d) Representative light microscope images of HUVEC/fibroblast angiogenesis assays for 654 
HUVECs co-cultured with empty alginate capsules (a), 100ng/ml VEGF (b), naked Tie2-655 
iBMMs (c) or alginate encapsulated Tie2-iBMMs (d). (e) HUVEC tubule area was compared 656 
(n=6-12/group, **P=0.01 ***P=0.0001 by Kruskal Wallis test, error bars=s.d.). (f) 657 
Quantification of PlGF-2, VEGF, MMP9, IL-10 and IL-1 secreted by nTie2-iBMMs (green) 658 
and eTie2-iBMMs (grey) following in vitro culture for up to 21 days (n=5/group, **P=0.01, 659 
***P=0.001, ****P<0.001 by 2way ANOVA and Bonferroni post-test, error bars=s.e.m.). 660 
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(g&h) Quantification of Vegfa164 (g) and MCP-1 (h) secreted by stimulated Tie2-iBMMs 661 
using ELISA (n=6/group, **P=0.01 by Mann Whitney test, error bars=s.d.).  662 
Fig. 4 The effect of alginate encapsulation on cell retention within the ischaemic murine 663 
hindlimb. (a) Tie2-iBMMs stained with VivoTrack680 biofluorescent dye were either directly 664 
injected (nTie2-iBMMs) into the ischaemic limb of mice or encapsulated within alginate 665 
(eTie2-iBMMs), and their retention tracked using an IVIS Spectrum In Vivo Imaging System 666 
over 28 days. (b) The average radiance efficiency at each time point was normalised to day 667 
0 and compared between treatment groups (n=4/group, P<0.0001 by 2way ANOVA *P=0.05 668 
**P=0.01 by Bonferroni post-test, error bars=s.e.m.). 669 
Fig. 5 The effect of cell encapsulation on revascularisation of the murine ischaemic hindlimb. 670 
(a) Laser Doppler images of mice treated with direct injection of naked or encapsulated Tie2-671 
iBMMs, or acellular alginate capsules, measured over 21 days (n=11-15/group). (b) 672 
Perfusion index of murine hindlimbs following induction of ischaemia up to day 21 (ischaemic 673 
limb flux/contralateral limb flux, P<0.05 by 2way ANOVA *P=0.05 **P=0.01 ***P=0.0001 by 674 
Bonferroni post-test, error bars=s.e.m.). (c&d) Mean α-SMA+ arteriole number per field of 675 
view (c) and diameter (d) in the adductor muscle of mice following HLI surgery at day 21 676 
(n=6-9/group, *P=0.05 ***P=0.001 by Kruskal Wallis test, error bars=s.d.). (e) Capillary 677 
fibre:ratio of gastrocnemius muscle samples harvested from mice at day 21 (CD31+ 678 
capillaries:laminin+ muscle fibres, n=6-9/group, *P=0.05 **P=0.01 by Kruskal Wallis test, 679 
error bars=s.d.). (f) Representative fluorescence microscopy images of arteriole staining for 680 
α-SMA (red) and laminin (green) and capillary/fibre staining for CD31 (red) and laminin 681 
(green). (g) Murine hindlimbs at day 21 treated with direct injection of naked or encapsulated 682 
cells (white arrow). (h) H&E analysis of capsules harvested from HLI mice at day 21. Scale 683 
bar = 100µm. 684 
Fig. 6 The effect of eTie2-iBMM treatment of the ischaemic hindlimb on inflammation, 685 
apoptosis and muscle damage. (a) CD45+ cells (white arrow) within the adductor muscle of 686 
nTie2-iBMM, eTie2-iBMM or empty capsule-treated mice. CD45+ cells were quantified as a 687 
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total proportion of DAPI-stained cells (iv, n=5/group, P=n/s by Kruskal Wallis test, error 688 
bars=s.e.m.). (b-d) Quantification of (b) neutrophil, (c) monocyte and (d) macrophage 689 
content of ischaemic hindlimb muscle after 7 days following delivery of nTie2-iBMMs (grey), 690 
eTie2-iBMMs (purple) or empty alginate capsules (white). Data are represented as a 691 
proportion of CD45+ cells (n=5/group, P=n/s by Kruskal Wallis test, error bars=s.d.). (e) 692 
Analysis of proportion of Ly6Chigh (purple) and Ly6Clow (grey) monocytes isolated from 693 
ischaemic muscle (n=5/group, P=0.05 by Kruskal Wallis test). (f) Representative 694 
fluorescence microscopy images of cells (blue, DAPI) expressing activated caspase-3 (red, 695 
white arrow) in adductor muscle specimens of ischaemic adductor muscle fibres from nTie2-696 
iBMM, eTie2-iBMM and empty alginate capsule treated mice; and H&E stained microscopy 697 
images of adductor muscle from nTie2-iBMM, eTie2-iBMM and empty alginate capsule-698 
treated mice. Quantification of (g) cells expressing activated caspase-3 (n=4/group, P=n/s by 699 
Kruskal Wallis test, error bars=s.e.m.) and (h) muscle damage/repair (n=5/group, P=n/s by 700 
Kruskal Wallis test, error bars=s.e.m.) in ischaemic adductor muscle from mice treated with 701 
nTie2-iBMMs, eTie2-iBMMs and empty alginate capsules. Scale bars =100µm 702 
